184 related articles for article (PubMed ID: 25103190)
1. In vitro and in vivo therapeutic approach for a small cell carcinoma of the ovary hypercalcaemic type using a SCCOHT-1 cellular model.
Otte A; Rauprich F; Hillemanns P; Park-Simon TW; von der Ohe J; Hass R
Orphanet J Rare Dis; 2014 Aug; 9():126. PubMed ID: 25103190
[TBL] [Abstract][Full Text] [Related]
2. c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations.
Otte A; Rauprich F; von der Ohe J; Yang Y; Kommoss F; Feuerhake F; Hillemanns P; Hass R
Oncotarget; 2015 Oct; 6(31):31640-58. PubMed ID: 26436697
[TBL] [Abstract][Full Text] [Related]
3. A tumor-derived population (SCCOHT-1) as cellular model for a small cell ovarian carcinoma of the hypercalcemic type.
Otte A; Göhring G; Steinemann D; Schlegelberger B; Groos S; Länger F; Kreipe HH; Schambach A; Neumann T; Hillemanns P; Park-Simon TW; Hass R
Int J Oncol; 2012 Aug; 41(2):765-75. PubMed ID: 22581215
[TBL] [Abstract][Full Text] [Related]
4. Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.
Wang Y; Chen SY; Colborne S; Lambert G; Shin CY; Santos ND; Orlando KA; Lang JD; Hendricks WPD; Bally MB; Karnezis AN; Hass R; Underhill TM; Morin GB; Trent JM; Weissman BE; Huntsman DG
Mol Cancer Ther; 2018 Dec; 17(12):2767-2779. PubMed ID: 30232145
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.
Lin DI; Chudnovsky Y; Duggan B; Zajchowski D; Greenbowe J; Ross JS; Gay LM; Ali SM; Elvin JA
Gynecol Oncol; 2017 Dec; 147(3):626-633. PubMed ID: 29102090
[TBL] [Abstract][Full Text] [Related]
6. The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.
Wang Y; Chen SY; Karnezis AN; Colborne S; Santos ND; Lang JD; Hendricks WP; Orlando KA; Yap D; Kommoss F; Bally MB; Morin GB; Trent JM; Weissman BE; Huntsman DG
J Pathol; 2017 Jul; 242(3):371-383. PubMed ID: 28444909
[TBL] [Abstract][Full Text] [Related]
7. Biallelic somatic SMARCA4 mutations in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
Bailey S; Murray MJ; Witkowski L; Hook E; Hasselblatt M; Crawford R; Foulkes WD; Tischkowitz M; Nicholson JC
Pediatr Blood Cancer; 2015 Apr; 62(4):728-30. PubMed ID: 25307865
[TBL] [Abstract][Full Text] [Related]
8. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
[TBL] [Abstract][Full Text] [Related]
9. Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts.
Connor YD; Miao D; Lin DI; Hayne C; Howitt BE; Dalrymple JL; DeLeonardis KR; Hacker MR; Esselen KM; Shea M
Gynecol Oncol; 2020 Apr; 157(1):106-114. PubMed ID: 31954538
[TBL] [Abstract][Full Text] [Related]
10. Interference of Ca²⁺ with the proliferation of SCCOHT-1 and ovarian adenocarcinoma cells.
Otte A; Rauprich F; von der Ohe J; Hillemanns P; Hass R
Int J Oncol; 2014 Sep; 45(3):1151-8. PubMed ID: 24969518
[TBL] [Abstract][Full Text] [Related]
11. Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond
Auguste A; Blanc-Durand F; Deloger M; Le Formal A; Bareja R; Wilkes DC; Richon C; Brunn B; Caron O; Devouassoux-Shisheboran M; Gouy S; Morice P; Bentivegna E; Sboner A; Elemento O; Rubin MA; Pautier P; Genestie C; Cyrta J; Leary A
Cells; 2020 Jun; 9(6):. PubMed ID: 32575483
[TBL] [Abstract][Full Text] [Related]
12. Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics.
Clarke BA; Witkowski L; Ton Nu TN; Shaw PA; Gilks CB; Huntsman D; Karnezis AN; Sebire N; Lamovec J; Roth LM; Stewart CJ; Hasselblatt M; Foulkes WD; McCluggage WG
Histopathology; 2016 Nov; 69(5):727-738. PubMed ID: 27100627
[TBL] [Abstract][Full Text] [Related]
13. Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type.
Ji JX; Cochrane DR; Tessier-Cloutier B; Chen SY; Ho G; Pathak KV; Alcazar IN; Farnell D; Leung S; Cheng A; Chow C; Colborne S; Negri GL; Kommoss F; Karnezis A; Morin GB; McAlpine JN; Gilks CB; Weissman BE; Trent JM; Hoang L; Pirrotte P; Wang Y; Huntsman DG
Clin Cancer Res; 2020 Aug; 26(16):4402-4413. PubMed ID: 32409304
[TBL] [Abstract][Full Text] [Related]
14. Small Cell Carcinoma of Ovary, Hypercalcemic Type: A Rare Case Report.
Coşkun Ç; Kurucu N; Usubutun A; Soyer T; Ozcan HN; Çelik Ertaş NB; Kutluk T
J Pediatr Adolesc Gynecol; 2023 Apr; 36(2):112-115. PubMed ID: 36243275
[TBL] [Abstract][Full Text] [Related]
15. Molecular analyses reveal close similarities between small cell carcinoma of the ovary, hypercalcemic type and atypical teratoid/rhabdoid tumor.
Fahiminiya S; Witkowski L; Nadaf J; Carrot-Zhang J; Goudie C; Hasselblatt M; Johann P; Kool M; Lee RS; Gayden T; Roberts CW; Biegel JA; Jabado N; Majewski J; Foulkes WD
Oncotarget; 2016 Jan; 7(2):1732-40. PubMed ID: 26646792
[TBL] [Abstract][Full Text] [Related]
16. Loss of SMARCA4 Expression Is Both Sensitive and Specific for the Diagnosis of Small Cell Carcinoma of Ovary, Hypercalcemic Type.
Conlon N; Silva A; Guerra E; Jelinic P; Schlappe BA; Olvera N; Mueller JJ; Tornos C; Jungbluth AA; Young RH; Oliva E; Levine D; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):395-403. PubMed ID: 26645725
[TBL] [Abstract][Full Text] [Related]
17. Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition.
Lang JD; Hendricks WPD; Orlando KA; Yin H; Kiefer J; Ramos P; Sharma R; Pirrotte P; Raupach EA; Sereduk C; Tang N; Liang WS; Washington M; Facista SJ; Zismann VL; Cousins EM; Major MB; Wang Y; Karnezis AN; Sekulic A; Hass R; Vanderhyden BC; Nair P; Weissman BE; Huntsman DG; Trent JM
Clin Cancer Res; 2018 Apr; 24(8):1932-1943. PubMed ID: 29440177
[No Abstract] [Full Text] [Related]
18. SMARCA4 (BRG1) loss of expression is a useful marker for the diagnosis of ovarian small cell carcinoma of the hypercalcemic type (ovarian rhabdoid tumor): a comprehensive analysis of 116 rare gynecologic tumors, 9 soft tissue tumors, and 9 melanomas.
Karanian-Philippe M; Velasco V; Longy M; Floquet A; Arnould L; Coindre JM; Le Naoures-Méar C; Averous G; Guyon F; MacGrogan G; Croce S
Am J Surg Pathol; 2015 Sep; 39(9):1197-205. PubMed ID: 26135561
[TBL] [Abstract][Full Text] [Related]
19. SCCOHT tumors acquire chemoresistance and protection by interacting mesenchymal stroma/stem cells within the tumor microenvironment.
Otte A; Yang Y; von der Ohe J; Melzer C; Hillemanns P; Feuerhake F; Hass R
Int J Oncol; 2016 Dec; 49(6):2453-2463. PubMed ID: 27748897
[TBL] [Abstract][Full Text] [Related]
20. Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 cases.
Callegaro-Filho D; Gershenson DM; Nick AM; Munsell MF; Ramirez PT; Eifel PJ; Euscher ED; Marques RM; Nicolau SM; Schmeler KM
Gynecol Oncol; 2016 Jan; 140(1):53-7. PubMed ID: 26546963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]